Privately held Zavante Therapeutics Inc. hopes an intravenous formulation of an epoxide antibiotic first approved 20 years ago might hold the answer to addressing multi-drug resistant complicated urinary tract infections (cUTI), and now has Phase III data demonstrating non-inferiority against a control regimen of existing antibiotic combination therapy.
The San Diego biotech reported on April 6 that the ZEUS trial of Zolyd (fosfomycin) showed non-inferiority against a control...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
